Earnings Feed
Start Free
Home/Filings/3/0001209191-23-043005
3//SEC Filing

Versant Affiliates Fund V, L.P. 3

Accession 0001209191-23-043005

CIK 0001764974other
View on SEC.govCompany Profile

Filed

Jul 19, 8:00 PM ET

Accepted

Jul 20, 9:46 PM ET

Size

42.3 KB

Accession

0001209191-23-043005

Insider Transaction Report

Form 3
Period: 2023-07-20
Turnstone Biologics Corp.TSBX
Versant Venture Capital V, L.P.
10% Owner
Holdings

  • Series C Preferred Stock

    (indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)
    → Common Stock (4,667 underlying)

  • Series C Preferred Stock

    (indirect: By Versant Affiliates Fund V, L.P.)
    → Common Stock (4,216 underlying)

  • Series B-1 Preferred Stock

    (indirect: By Versant Venture Capital V, L.P.)
    → Common Stock (442,055 underlying)

  • Series B-1 Preferred Stock

    (indirect: By Versant Venture Capital V (Canada) LP)
    → Common Stock (33,642 underlying)

  • Series B-1 Preferred Stock

    (indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)
    → Common Stock (14,739 underlying)

  • Series B-1 Preferred Stock

    (indirect: By Versant Affiliates Fund V, L.P.)
    → Common Stock (13,297 underlying)

  • Series B-2 Preferred Stock

    (indirect: By Versant Venture Capital V (Canada) LP)
    → Common Stock (72,892 underlying)

  • Series B-2 Preferred Stock

    (indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)
    → Common Stock (31,936 underlying)

  • Series B-2 Preferred Stock

    (indirect: By Versant Affiliates Fund V, L.P.)
    → Common Stock (28,810 underlying)

  • Series D Preferred Stock

    (indirect: By Versant Vantage II, L.P.)
    → Common Stock (274,990 underlying)

  • Series A Preferred Stock

    (indirect: By Versant Venture Capital V, L.P.)
    → Common Stock (988,832 underlying)

  • Series A Preferred Stock

    (indirect: By Versant Venture Capital V (Canada) LP)
    → Common Stock (75,255 underlying)

  • Series A Preferred Stock

    (indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)
    → Common Stock (32,971 underlying)

  • Series A Preferred Stock

    (indirect: By Versant Affiliates Fund V, L.P.)
    → Common Stock (29,744 underlying)

  • Series C Preferred Stock

    (indirect: By Versant Venture Capital V, L.P.)
    → Common Stock (140,190 underlying)

  • Series C Preferred Stock

    (indirect: By Versant Venture Capital V (Canada) LP)
    → Common Stock (10,669 underlying)

  • Series B-2 Preferred Stock

    (indirect: By Versant Venture Capital V, L.P.)
    → Common Stock (957,787 underlying)
Versant Affiliates Fund V, L.P.
10% Owner
Holdings

  • Series B-2 Preferred Stock

    (indirect: By Versant Venture Capital V (Canada) LP)
    → Common Stock (72,892 underlying)

  • Series B-2 Preferred Stock

    (indirect: By Versant Affiliates Fund V, L.P.)
    → Common Stock (28,810 underlying)

  • Series C Preferred Stock

    (indirect: By Versant Venture Capital V (Canada) LP)
    → Common Stock (10,669 underlying)

  • Series B-1 Preferred Stock

    (indirect: By Versant Venture Capital V, L.P.)
    → Common Stock (442,055 underlying)

  • Series C Preferred Stock

    (indirect: By Versant Affiliates Fund V, L.P.)
    → Common Stock (4,216 underlying)

  • Series D Preferred Stock

    (indirect: By Versant Vantage II, L.P.)
    → Common Stock (274,990 underlying)

  • Series C Preferred Stock

    (indirect: By Versant Venture Capital V, L.P.)
    → Common Stock (140,190 underlying)

  • Series A Preferred Stock

    (indirect: By Versant Affiliates Fund V, L.P.)
    → Common Stock (29,744 underlying)

  • Series B-2 Preferred Stock

    (indirect: By Versant Venture Capital V, L.P.)
    → Common Stock (957,787 underlying)

  • Series A Preferred Stock

    (indirect: By Versant Venture Capital V, L.P.)
    → Common Stock (988,832 underlying)

  • Series A Preferred Stock

    (indirect: By Versant Venture Capital V (Canada) LP)
    → Common Stock (75,255 underlying)

  • Series A Preferred Stock

    (indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)
    → Common Stock (32,971 underlying)

  • Series B-1 Preferred Stock

    (indirect: By Versant Venture Capital V (Canada) LP)
    → Common Stock (33,642 underlying)

  • Series B-1 Preferred Stock

    (indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)
    → Common Stock (14,739 underlying)

  • Series B-1 Preferred Stock

    (indirect: By Versant Affiliates Fund V, L.P.)
    → Common Stock (13,297 underlying)

  • Series C Preferred Stock

    (indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)
    → Common Stock (4,667 underlying)

  • Series B-2 Preferred Stock

    (indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)
    → Common Stock (31,936 underlying)
Versant Vantage II GP-GP, LLC
10% Owner
Holdings

  • Series A Preferred Stock

    (indirect: By Versant Venture Capital V, L.P.)
    → Common Stock (988,832 underlying)

  • Series A Preferred Stock

    (indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)
    → Common Stock (32,971 underlying)

  • Series B-1 Preferred Stock

    (indirect: By Versant Affiliates Fund V, L.P.)
    → Common Stock (13,297 underlying)

  • Series A Preferred Stock

    (indirect: By Versant Venture Capital V (Canada) LP)
    → Common Stock (75,255 underlying)

  • Series B-2 Preferred Stock

    (indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)
    → Common Stock (31,936 underlying)

  • Series C Preferred Stock

    (indirect: By Versant Venture Capital V, L.P.)
    → Common Stock (140,190 underlying)

  • Series D Preferred Stock

    (indirect: By Versant Vantage II, L.P.)
    → Common Stock (274,990 underlying)

  • Series B-1 Preferred Stock

    (indirect: By Versant Venture Capital V, L.P.)
    → Common Stock (442,055 underlying)

  • Series B-1 Preferred Stock

    (indirect: By Versant Venture Capital V (Canada) LP)
    → Common Stock (33,642 underlying)

  • Series B-2 Preferred Stock

    (indirect: By Versant Venture Capital V, L.P.)
    → Common Stock (957,787 underlying)

  • Series A Preferred Stock

    (indirect: By Versant Affiliates Fund V, L.P.)
    → Common Stock (29,744 underlying)

  • Series B-1 Preferred Stock

    (indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)
    → Common Stock (14,739 underlying)

  • Series B-2 Preferred Stock

    (indirect: By Versant Venture Capital V (Canada) LP)
    → Common Stock (72,892 underlying)

  • Series C Preferred Stock

    (indirect: By Versant Venture Capital V (Canada) LP)
    → Common Stock (10,669 underlying)

  • Series C Preferred Stock

    (indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)
    → Common Stock (4,667 underlying)

  • Series B-2 Preferred Stock

    (indirect: By Versant Affiliates Fund V, L.P.)
    → Common Stock (28,810 underlying)

  • Series C Preferred Stock

    (indirect: By Versant Affiliates Fund V, L.P.)
    → Common Stock (4,216 underlying)
Versant Ventures V, LLC
10% Owner
Holdings

  • Series B-1 Preferred Stock

    (indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)
    → Common Stock (14,739 underlying)

  • Series C Preferred Stock

    (indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)
    → Common Stock (4,667 underlying)

  • Series C Preferred Stock

    (indirect: By Versant Affiliates Fund V, L.P.)
    → Common Stock (4,216 underlying)

  • Series A Preferred Stock

    (indirect: By Versant Venture Capital V (Canada) LP)
    → Common Stock (75,255 underlying)

  • Series A Preferred Stock

    (indirect: By Versant Affiliates Fund V, L.P.)
    → Common Stock (29,744 underlying)

  • Series B-1 Preferred Stock

    (indirect: By Versant Venture Capital V, L.P.)
    → Common Stock (442,055 underlying)

  • Series A Preferred Stock

    (indirect: By Versant Venture Capital V, L.P.)
    → Common Stock (988,832 underlying)

  • Series A Preferred Stock

    (indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)
    → Common Stock (32,971 underlying)

  • Series B-1 Preferred Stock

    (indirect: By Versant Venture Capital V (Canada) LP)
    → Common Stock (33,642 underlying)

  • Series B-2 Preferred Stock

    (indirect: By Versant Venture Capital V, L.P.)
    → Common Stock (957,787 underlying)

  • Series B-2 Preferred Stock

    (indirect: By Versant Affiliates Fund V, L.P.)
    → Common Stock (28,810 underlying)

  • Series C Preferred Stock

    (indirect: By Versant Venture Capital V (Canada) LP)
    → Common Stock (10,669 underlying)

  • Series B-1 Preferred Stock

    (indirect: By Versant Affiliates Fund V, L.P.)
    → Common Stock (13,297 underlying)

  • Series B-2 Preferred Stock

    (indirect: By Versant Venture Capital V (Canada) LP)
    → Common Stock (72,892 underlying)

  • Series B-2 Preferred Stock

    (indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)
    → Common Stock (31,936 underlying)

  • Series C Preferred Stock

    (indirect: By Versant Venture Capital V, L.P.)
    → Common Stock (140,190 underlying)

  • Series D Preferred Stock

    (indirect: By Versant Vantage II, L.P.)
    → Common Stock (274,990 underlying)
Versant Vantage II GP, L.P.
10% Owner
Holdings

  • Series A Preferred Stock

    (indirect: By Versant Venture Capital V, L.P.)
    → Common Stock (988,832 underlying)

  • Series D Preferred Stock

    (indirect: By Versant Vantage II, L.P.)
    → Common Stock (274,990 underlying)

  • Series B-2 Preferred Stock

    (indirect: By Versant Venture Capital V, L.P.)
    → Common Stock (957,787 underlying)

  • Series B-2 Preferred Stock

    (indirect: By Versant Venture Capital V (Canada) LP)
    → Common Stock (72,892 underlying)

  • Series B-2 Preferred Stock

    (indirect: By Versant Affiliates Fund V, L.P.)
    → Common Stock (28,810 underlying)

  • Series A Preferred Stock

    (indirect: By Versant Venture Capital V (Canada) LP)
    → Common Stock (75,255 underlying)

  • Series B-1 Preferred Stock

    (indirect: By Versant Affiliates Fund V, L.P.)
    → Common Stock (13,297 underlying)

  • Series C Preferred Stock

    (indirect: By Versant Affiliates Fund V, L.P.)
    → Common Stock (4,216 underlying)

  • Series A Preferred Stock

    (indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)
    → Common Stock (32,971 underlying)

  • Series B-1 Preferred Stock

    (indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)
    → Common Stock (14,739 underlying)

  • Series C Preferred Stock

    (indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)
    → Common Stock (4,667 underlying)

  • Series A Preferred Stock

    (indirect: By Versant Affiliates Fund V, L.P.)
    → Common Stock (29,744 underlying)

  • Series B-1 Preferred Stock

    (indirect: By Versant Venture Capital V, L.P.)
    → Common Stock (442,055 underlying)

  • Series B-1 Preferred Stock

    (indirect: By Versant Venture Capital V (Canada) LP)
    → Common Stock (33,642 underlying)

  • Series B-2 Preferred Stock

    (indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)
    → Common Stock (31,936 underlying)

  • Series C Preferred Stock

    (indirect: By Versant Venture Capital V, L.P.)
    → Common Stock (140,190 underlying)

  • Series C Preferred Stock

    (indirect: By Versant Venture Capital V (Canada) LP)
    → Common Stock (10,669 underlying)
Versant Vantage II, L.P.
10% Owner
Holdings

  • Series A Preferred Stock

    (indirect: By Versant Venture Capital V, L.P.)
    → Common Stock (988,832 underlying)

  • Series B-1 Preferred Stock

    (indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)
    → Common Stock (14,739 underlying)

  • Series C Preferred Stock

    (indirect: By Versant Venture Capital V, L.P.)
    → Common Stock (140,190 underlying)

  • Series B-1 Preferred Stock

    (indirect: By Versant Affiliates Fund V, L.P.)
    → Common Stock (13,297 underlying)

  • Series B-2 Preferred Stock

    (indirect: By Versant Venture Capital V, L.P.)
    → Common Stock (957,787 underlying)

  • Series B-2 Preferred Stock

    (indirect: By Versant Venture Capital V (Canada) LP)
    → Common Stock (72,892 underlying)

  • Series B-2 Preferred Stock

    (indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)
    → Common Stock (31,936 underlying)

  • Series C Preferred Stock

    (indirect: By Versant Affiliates Fund V, L.P.)
    → Common Stock (4,216 underlying)

  • Series D Preferred Stock

    (indirect: By Versant Vantage II, L.P.)
    → Common Stock (274,990 underlying)

  • Series A Preferred Stock

    (indirect: By Versant Venture Capital V (Canada) LP)
    → Common Stock (75,255 underlying)

  • Series A Preferred Stock

    (indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)
    → Common Stock (32,971 underlying)

  • Series A Preferred Stock

    (indirect: By Versant Affiliates Fund V, L.P.)
    → Common Stock (29,744 underlying)

  • Series B-1 Preferred Stock

    (indirect: By Versant Venture Capital V, L.P.)
    → Common Stock (442,055 underlying)

  • Series B-1 Preferred Stock

    (indirect: By Versant Venture Capital V (Canada) LP)
    → Common Stock (33,642 underlying)

  • Series B-2 Preferred Stock

    (indirect: By Versant Affiliates Fund V, L.P.)
    → Common Stock (28,810 underlying)

  • Series C Preferred Stock

    (indirect: By Versant Venture Capital V (Canada) LP)
    → Common Stock (10,669 underlying)

  • Series C Preferred Stock

    (indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)
    → Common Stock (4,667 underlying)
Versant Ophthalmic Affiliates I, L.P.
10% Owner
Holdings

  • Series B-1 Preferred Stock

    (indirect: By Versant Venture Capital V (Canada) LP)
    → Common Stock (33,642 underlying)

  • Series B-2 Preferred Stock

    (indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)
    → Common Stock (31,936 underlying)

  • Series C Preferred Stock

    (indirect: By Versant Venture Capital V, L.P.)
    → Common Stock (140,190 underlying)

  • Series C Preferred Stock

    (indirect: By Versant Venture Capital V (Canada) LP)
    → Common Stock (10,669 underlying)

  • Series C Preferred Stock

    (indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)
    → Common Stock (4,667 underlying)

  • Series C Preferred Stock

    (indirect: By Versant Affiliates Fund V, L.P.)
    → Common Stock (4,216 underlying)

  • Series D Preferred Stock

    (indirect: By Versant Vantage II, L.P.)
    → Common Stock (274,990 underlying)

  • Series B-1 Preferred Stock

    (indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)
    → Common Stock (14,739 underlying)

  • Series A Preferred Stock

    (indirect: By Versant Venture Capital V, L.P.)
    → Common Stock (988,832 underlying)

  • Series A Preferred Stock

    (indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)
    → Common Stock (32,971 underlying)

  • Series A Preferred Stock

    (indirect: By Versant Affiliates Fund V, L.P.)
    → Common Stock (29,744 underlying)

  • Series B-2 Preferred Stock

    (indirect: By Versant Venture Capital V, L.P.)
    → Common Stock (957,787 underlying)

  • Series B-2 Preferred Stock

    (indirect: By Versant Affiliates Fund V, L.P.)
    → Common Stock (28,810 underlying)

  • Series A Preferred Stock

    (indirect: By Versant Venture Capital V (Canada) LP)
    → Common Stock (75,255 underlying)

  • Series B-1 Preferred Stock

    (indirect: By Versant Venture Capital V, L.P.)
    → Common Stock (442,055 underlying)

  • Series B-1 Preferred Stock

    (indirect: By Versant Affiliates Fund V, L.P.)
    → Common Stock (13,297 underlying)

  • Series B-2 Preferred Stock

    (indirect: By Versant Venture Capital V (Canada) LP)
    → Common Stock (72,892 underlying)
Versant Ventures V GP-GP (Canada), Inc.
10% Owner
Holdings

  • Series A Preferred Stock

    (indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)
    → Common Stock (32,971 underlying)

  • Series A Preferred Stock

    (indirect: By Versant Affiliates Fund V, L.P.)
    → Common Stock (29,744 underlying)

  • Series C Preferred Stock

    (indirect: By Versant Venture Capital V, L.P.)
    → Common Stock (140,190 underlying)

  • Series C Preferred Stock

    (indirect: By Versant Venture Capital V (Canada) LP)
    → Common Stock (10,669 underlying)

  • Series D Preferred Stock

    (indirect: By Versant Vantage II, L.P.)
    → Common Stock (274,990 underlying)

  • Series A Preferred Stock

    (indirect: By Versant Venture Capital V, L.P.)
    → Common Stock (988,832 underlying)

  • Series A Preferred Stock

    (indirect: By Versant Venture Capital V (Canada) LP)
    → Common Stock (75,255 underlying)

  • Series B-1 Preferred Stock

    (indirect: By Versant Affiliates Fund V, L.P.)
    → Common Stock (13,297 underlying)

  • Series B-1 Preferred Stock

    (indirect: By Versant Venture Capital V, L.P.)
    → Common Stock (442,055 underlying)

  • Series B-1 Preferred Stock

    (indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)
    → Common Stock (14,739 underlying)

  • Series B-2 Preferred Stock

    (indirect: By Versant Venture Capital V, L.P.)
    → Common Stock (957,787 underlying)

  • Series B-2 Preferred Stock

    (indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)
    → Common Stock (31,936 underlying)

  • Series B-1 Preferred Stock

    (indirect: By Versant Venture Capital V (Canada) LP)
    → Common Stock (33,642 underlying)

  • Series B-2 Preferred Stock

    (indirect: By Versant Venture Capital V (Canada) LP)
    → Common Stock (72,892 underlying)

  • Series B-2 Preferred Stock

    (indirect: By Versant Affiliates Fund V, L.P.)
    → Common Stock (28,810 underlying)

  • Series C Preferred Stock

    (indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)
    → Common Stock (4,667 underlying)

  • Series C Preferred Stock

    (indirect: By Versant Affiliates Fund V, L.P.)
    → Common Stock (4,216 underlying)
Versant Ventures V (Canada), L.P.
10% Owner
Holdings

  • Series A Preferred Stock

    (indirect: By Versant Venture Capital V (Canada) LP)
    → Common Stock (75,255 underlying)

  • Series B-1 Preferred Stock

    (indirect: By Versant Venture Capital V, L.P.)
    → Common Stock (442,055 underlying)

  • Series B-2 Preferred Stock

    (indirect: By Versant Affiliates Fund V, L.P.)
    → Common Stock (28,810 underlying)

  • Series C Preferred Stock

    (indirect: By Versant Venture Capital V, L.P.)
    → Common Stock (140,190 underlying)

  • Series B-1 Preferred Stock

    (indirect: By Versant Venture Capital V (Canada) LP)
    → Common Stock (33,642 underlying)

  • Series B-1 Preferred Stock

    (indirect: By Versant Affiliates Fund V, L.P.)
    → Common Stock (13,297 underlying)

  • Series B-2 Preferred Stock

    (indirect: By Versant Venture Capital V, L.P.)
    → Common Stock (957,787 underlying)

  • Series A Preferred Stock

    (indirect: By Versant Affiliates Fund V, L.P.)
    → Common Stock (29,744 underlying)

  • Series B-2 Preferred Stock

    (indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)
    → Common Stock (31,936 underlying)

  • Series A Preferred Stock

    (indirect: By Versant Venture Capital V, L.P.)
    → Common Stock (988,832 underlying)

  • Series A Preferred Stock

    (indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)
    → Common Stock (32,971 underlying)

  • Series B-1 Preferred Stock

    (indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)
    → Common Stock (14,739 underlying)

  • Series B-2 Preferred Stock

    (indirect: By Versant Venture Capital V (Canada) LP)
    → Common Stock (72,892 underlying)

  • Series D Preferred Stock

    (indirect: By Versant Vantage II, L.P.)
    → Common Stock (274,990 underlying)

  • Series C Preferred Stock

    (indirect: By Versant Venture Capital V (Canada) LP)
    → Common Stock (10,669 underlying)

  • Series C Preferred Stock

    (indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)
    → Common Stock (4,667 underlying)

  • Series C Preferred Stock

    (indirect: By Versant Affiliates Fund V, L.P.)
    → Common Stock (4,216 underlying)
Versant Venture Capital V (Canada), LP
10% Owner
Holdings

  • Series C Preferred Stock

    (indirect: By Versant Venture Capital V, L.P.)
    → Common Stock (140,190 underlying)

  • Series A Preferred Stock

    (indirect: By Versant Venture Capital V, L.P.)
    → Common Stock (988,832 underlying)

  • Series B-1 Preferred Stock

    (indirect: By Versant Venture Capital V, L.P.)
    → Common Stock (442,055 underlying)

  • Series B-1 Preferred Stock

    (indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)
    → Common Stock (14,739 underlying)

  • Series D Preferred Stock

    (indirect: By Versant Vantage II, L.P.)
    → Common Stock (274,990 underlying)

  • Series A Preferred Stock

    (indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)
    → Common Stock (32,971 underlying)

  • Series B-1 Preferred Stock

    (indirect: By Versant Affiliates Fund V, L.P.)
    → Common Stock (13,297 underlying)

  • Series B-2 Preferred Stock

    (indirect: By Versant Venture Capital V (Canada) LP)
    → Common Stock (72,892 underlying)

  • Series B-2 Preferred Stock

    (indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)
    → Common Stock (31,936 underlying)

  • Series C Preferred Stock

    (indirect: By Versant Venture Capital V (Canada) LP)
    → Common Stock (10,669 underlying)

  • Series C Preferred Stock

    (indirect: By Versant Ophthalmic Affiliates Fund I, L.P.)
    → Common Stock (4,667 underlying)

  • Series C Preferred Stock

    (indirect: By Versant Affiliates Fund V, L.P.)
    → Common Stock (4,216 underlying)

  • Series A Preferred Stock

    (indirect: By Versant Venture Capital V (Canada) LP)
    → Common Stock (75,255 underlying)

  • Series A Preferred Stock

    (indirect: By Versant Affiliates Fund V, L.P.)
    → Common Stock (29,744 underlying)

  • Series B-1 Preferred Stock

    (indirect: By Versant Venture Capital V (Canada) LP)
    → Common Stock (33,642 underlying)

  • Series B-2 Preferred Stock

    (indirect: By Versant Venture Capital V, L.P.)
    → Common Stock (957,787 underlying)

  • Series B-2 Preferred Stock

    (indirect: By Versant Affiliates Fund V, L.P.)
    → Common Stock (28,810 underlying)
Footnotes (6)
  • [F1]Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock will automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date.
  • [F2]Shares are held by Versant Venture Capital V, L.P. ("Versant V"). Versant Ventures V, LLC ("Versant V GP") is the sole general partner of Versant V. Jerel C. Davis is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Versant V. Each of the Reporting Persons disclaims beneficial ownership of the shares held by Versant V, except to the extent of its respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.
  • [F3]Shares are held by Versant Venture Capital V (Canada) LP ("Canada V"). Versant Ventures V (Canada), L.P. ("Canada V GP") is the general partner of Canada V and Versant Ventures V GP-GP (Canada), Inc. ("Canada V GP-GP") is the sole general partner of Canada V GP. Jerel C. Davis is a director of Canada V GP-GP and may be deemed to share voting and dispositive power over the shares held by Canada V. Each of the Reporting Persons disclaims beneficial ownership of the shares held by Canada V, except to the extent of its respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.
  • [F4]Shares are held by Versant Ophthalmic Affiliates Fund I, L.P. ("Ophthalmic"). Versant V GP is the sole general partner of Ophthalmic. Jerel C. Davis is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Ophthalmic. Each of the Reporting Persons disclaims beneficial ownership of the shares held by Ophthalmic, except to the extent of its respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.
  • [F5]Shares are held by Versant Affiliates Fund V, L.P. ("Affiliates V"). Versant V GP is the sole general partner of Affiliates V. Jerel C. Davis is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Affiliates V. Each of the Reporting Persons disclaims beneficial ownership of the shares held by Affiliates, except to the extent of its respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.
  • [F6]Shares held by Versant Vantage II, L.P. ("Vantage II"). Versant Vantage II GP, L.P. ("Vantage II GP") is the sole general partner of Vantage II and Versant Vantage II GP-GP, LLC (Vantage II GP-GP") is the sole general partner of Vantage II GP. Jerel C. Davis is a managing director of Vantage II GP-GP and may be deemed to share voting and dispositive power over the shares held by Vantage II. Each of the Reporting Persons disclaims beneficial ownership of the shares held by Canada V, except to the extent of its respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.

Documents

1 file

Issuer

Turnstone Biologics Corp.

CIK 0001764974

→
Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001589095

Filing Metadata

Form type
3
Filed
Jul 19, 8:00 PM ET
Accepted
Jul 20, 9:46 PM ET
Size
42.3 KB
View on SEC.gov